- Business
- Chimin Health Management Co., Ltd. (603222.SS) researches, develops, produces and sells pharmaceuticals, medical devices and comprehensive medical services in China and internationally. The company offers core pharmaceutical products including nearly 40 varieties of large-volume infusions such as balanced, nutritional, therapeutic infusions and external irrigation agents in non-PVC soft bags and disposable polypropylene plastic bottles; its flagship double-pipe double-valve non-PVC soft bag infusion holds over 30% market share in East and South China and exports to more than 30 countries in Southeast Asia, Africa and South America. Medical devices encompass safety self-destruct syringes, safety injection needles, sterile syringes, irrigators, insulin syringes, infusion sets, precision filter infusion sets, hemodialysis concentrates and other injection puncture products; in vitro diagnostic reagents cover clinical chemistry, immunological, blood testing, rapid and enzyme-linked diagnostics, with laboratory instruments and kits like FOB fecal occult blood and Helicobacter pylori detection; comprehensive medical services operate 18 hemodialysis centers and three general hospitals including Boao International Hospital. Founded in 1996 and headquartered in Huangyan District, Taizhou City, Zhejiang Province, China, Chimin maintains three production bases in Zhejiang, Shanghai and Spain, plus nine subsidiaries such as Shanghai Jumin Biotechnology Co., Ltd., Taizhou Jurui Plastic Technology Co., Ltd., Spain Linear Chemical Co., Ltd. and Hainan Jumin Boao International Hospital Co., Ltd.; it pursues a "comprehensive health strategy" of one main business (medical services) and two wings (pharmaceuticals and devices). Recent developments include acceptance on September 26, 2025, by China's National Medical Products Administration of a clinical trial application for DB006 oncolytic adenovirus injection by subsidiary Boao International Hospital to treat advanced malignant solid tumors; a May 2025 strategic cooperation framework agreement between Boao International Hospital and Dabo Biotech for new drug development and clinical transformation in Hainan's Lecheng Pilot Zone; cumulative repurchase of 2.0055 million shares as of November 30, 2025, under a CNY 200 million program initiated in March 2025; and ongoing partnerships with U.S. firm RTI, United Nations Red Cross, Oda Hospital for cell therapy technologies, Italian University of Turin and domestic research institutions.